Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a revolutionary class of drugs beyond diabetes care. Widely used in type 2 diabetes and obesity management, they also show promise in neurodegenerative disorders like Alzheimer’s and Parkinson’s disease. Acting through multiple mechanisms—enhancing insulin secretion, reducing glucagon, slowing gastric emptying, improving satiety, and regulating lipid metabolism—GLP-1 RAs provide comprehensive benefits including weight